MedTrace Logo

A Phase I/II Study of GX15-070MS in Untreated CLL

NCT00600964 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2014-05-12

No results posted yet for this study

Summary

This protocol is being run to determine the best phase II dose and schedule of obatoclax in patients with previously untreated CLL.

Conditions

Interventions

DRUG

GX15-070MS

A 60-minute or 3-hour IV infusion every 2-3 weeks.

DRUG

GX15-070MS

GX15-070MS at various doses and schedules

Sponsors & Collaborators

  • Gemin X

    lead INDUSTRY

Principal Investigators

  • Jean Viallet, MD · Gemin X, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600964 on ClinicalTrials.gov